Skip to main content

Regeneron Pharmaceuticals Libtayo revenue

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

Libtayo revenue at Regeneron Pharmaceuticals came to $550.0M for the quarter to 30 Sep 2026, up 50.6% from a year earlier.

As Regeneron Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$243.8MDec 2023$263.9MMar 2024$297.4MJun 2024$288.6MSep 2024$366.9MDec 2024$285.1MMar 2025$376.5MJun 2025$365.2MSep 2025$425.4MDec 2025$438.2MMar 2026$489.4MJun 2026$550.0MSep 2026
Regeneron Pharmaceuticals Libtayo revenue, every reported period
Period endingLibtayo revenueChange on a yearFiled
30 Sep 2026$550.0Mup 50.6%30 Oct 2026
30 Jun 2026$489.4Mup 30.0%30 Jul 2026
31 Mar 2026$438.2Mup 53.7%29 Apr 2026
31 Dec 2025$425.4Mup 15.9%4 Feb 2026
30 Sep 2025$365.2Mup 26.5%28 Oct 2025
30 Jun 2025$376.5Mup 26.6%1 Aug 2025
31 Mar 2025$285.1Mup 8.0%29 Apr 2025
31 Dec 2024$366.9Mup 50.5%5 Feb 2025
30 Sep 2024$288.6Mup 24.2%31 Oct 2024
30 Jun 2024$297.4Mup 41.6%1 Aug 2024
31 Mar 2024$263.9Mup 49.2%2 May 2024
31 Dec 2023$243.8M—5 Feb 2024
30 Sep 2023$232.4M—2 Nov 2023
30 Jun 2023$210.0M—3 Aug 2023
31 Mar 2023$176.9M—4 May 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Regeneron Pharmaceuticals: Collaboration revenue · Net product sales · Lynozyfic revenue · EYLEA HD And EYLEA revenue · EYLEA HD revenue · EYLEA revenue · Praluent revenue · Evkeeza revenue · financial statements

Every KPI and segment of REGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.